Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India ...

Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...

A radical shifting of trade flows has given Ireland the second-biggest trade imbalance with the U.S. after China, mostly due to demand for weight-loss drugs.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.